| HS Code | 432130 |
| Product Name | Egg Drop Syndrome Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Vaccine Type | Inactivated (killed) whole virus vaccine antigen |
| Antigen Source | Egg Drop Syndrome Virus (Adenovirus group 1) propagated in cell culture or embryonated eggs |
| Physical State | Liquid bulk antigen or lyophilized powder for formulation |
| Inactivating Agent | Formaldehyde, beta-propiolactone, or binary ethylenimine |
| Adjuvant System | Oil emulsion, aluminum hydroxide, or alternative approved adjuvant depending on final dosage form |
| Target Species | Poultry, especially laying hens and breeding flocks |
| Clinical Indication | Active immunization against egg drop syndrome to prevent reduction in egg production and poor eggshell quality |
| Route Of Administration | Intramuscular, subcutaneous, or as specified by final veterinary formulation |
As an accredited Egg Drop Syndrome Vaccine,Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Each pack contains 100 mL in sterile glass vials, sealed with rubber stoppers and aluminum caps for optimal stability. |
| Container Loading (20′ FCL) | Container loading: one 20′ FCL of Egg Drop Syndrome Vaccine (Inactivated) veterinary grade API, palletized and secured for transport. |
| Shipping | Shipping requires strict cold-chain handling (2–8°C) to maintain potency. Packaging meets IATA/ADR regulations for biological substances, with insulated containers, gel packs, and temperature loggers. Export documentation includes veterinary certificates and MSDS. Deliveries are tracked, with priority dispatch and dry-ice options for international air freight. Ensure compliance with destination country import permits. |
| Storage | Store at 2–8°C in a cool, dry place, protected from light and moisture. Do not freeze or expose to excessive heat. Keep in original, tightly closed container. For veterinary use only; store away from food and reach of children. Use before expiry. |
| Shelf Life | Shelf life: 24 months when stored at 2–8°C, protected from light, in unopened original containers. |
In laying and breeding poultry operations, the inactivated EDSV antigen API is formulated into a water-in-oil (W/O) emulsion for intramuscular or subcutaneous administration at 16–18 weeks of age, prior to the onset of lay. The aqueous antigen phase is blended into a mineral oil continuous phase at 45–55 wt% using a rotor-stator high-shear mixer; the resultant emulsion is characterized by a droplet size distribution with Dv90 ≤ 5 µm measured by laser diffraction per ISO 13320:2020 and a viscosity of 30–80 mPa·s at 25 °C by ISO 2555. A single dose of 0.5 mL per bird is standard in multivalent layer programmes, but the exact antigen mass per dose is defined by established protective dose data from vaccination-challenge studies, not by concentration alone. Inactivation validation for the API includes kinetic studies on the inactivation agent, with residual free formaldehyde maintained at ≤0.02% where formalin is used, and sterility confirmed by direct inoculation as described in Ph. Eur. 2.6.1. Endotoxin burden is controlled to ≤10 EU/mL for aqueous API intermediates where a specification is imposed, using Ph. Eur. 2.6.14. Emulsion failure modes observed on production lines include creaming after 24 h static storage at 37 °C, crack formation during accelerated stability at 4 °C, and droplet coalescence following excessive back-pressure in piston-filling lines; these defects are minimized by controlling the aqueous phase pH to 7.0–7.4 and by pre-conditioning the oil phase to 20–25 °C before emulsification. Tablet and capsule dosage forms for this inactivated viral antigen do not appear in current veterinary vaccine compendia; the listing reflects general API dossier formatting rather than a licensed oral solid vaccine route, so the documented downstream tracks are injectable emulsion, aqueous concentrate, freeze-dried diagnostic powder, and autogenous antigen bank configurations.
When EDSV antigen is combined with inactivated Newcastle disease virus and infectious bronchitis virus antigens in a single emulsion, the blending sequence determines whether antigen adsorption, competitive depletion of emulsifier, or pH drift compromises the haemagglutination titre of the EDSV component. The aqueous antigen pool is typically prepared at 2–8 °C with a total protein load not exceeding 200 µg/mL unless compatibility data support higher loading, because excess non-viral protein from allantoic fluid can destabilize the oil-water interface. Antigen load is expressed as pre-inactivation haemagglutinating units per dose, but the final formulation is adjusted not by volume replacement alone; each antigen must be titrated in the presence of the other components to detect masking of HI reactivity. A typical compatibility panel includes EDSV antigen pooled at 6.0–8.0 log2 HI units per monovalent fraction with NDV LaSota and IBV M41 antigens. The critical process window is the post-emulsification holding time before filling: at 20–25 °C, a hold of more than 4 h in stainless-steel transfer vessels has been associated with upward drift in emulsion droplet median diameter from 1.2 µm to 3.8 µm and a measurable loss of EDSV haemagglutination titre in accelerated compatibility studies. Recirculation loops with peristaltic pumps should be configured to generate shear rates below 10,000 s⁻¹ to limit antigen aggregation. Compliance for extraneous agents and freedom from residual live EDSV is evaluated using Ph. Eur. 5.1.7 as a viral safety framework, while batch potency release follows vaccination-challenge or serological readouts described in the applicable avian vaccine monograph. The main operational boundary is that polyvalent emulsions cannot be terminally sterile-filtered because the emulsion droplet size exceeds 0.22 µm membrane pore ratings; aseptic assembly of pre-sterilized components is mandatory. Published data for EDSV-specific antigen load ceilings in four-way or five-way combinations are limited, so each formulation change requires a new compatibility matrix rather than reliance on historical NDV-IBV blend data.
Autogenous inactivated EDSV antigen programmes begin with field isolate submission from a defined production complex, followed by adaptation of the isolate to duck embryo fibroblast or allantoic cavity propagation. The resulting infectious harvest is clarified through depth filtration and a 0.45 µm membrane pre-filter before inactivation; the target pre-inactivation haemagglutination titre is generally specified by the manufacturing authorization, with autogenous producers frequently setting a minimum of 8.0 log2 HA units/0.025 mL before inactivation to allow downstream blending without over-concentration. Inactivation kinetics are established for each batch using binary ethyleneimine or formaldehyde, with a minimum of 3 log10 reduction demonstrated by two consecutive passages in 9-day-old embryonated duck eggs. This inactivation curve is not a fixed time-temperature constant; temperature coefficients vary with residual organic nitrogen load in clarified allantoic fluid, so the protocol requires sampling at 0 h, 6 h, 12 h, and 24 h post-inactivation to confirm the line of inactivation. The inactivated antigen is then concentrated and diafiltered against a phosphate-buffered saline matrix using tangential flow filtration cassettes with a molecular weight cut-off suitable for adenovirus-sized particles, commonly 100 kDa or 300 kDa depending on host-cell protein removal targets. Final antigen batch release includes sterility per Ph. Eur. 2.6.1, absence of residual infectious EDSV per the OIE Terrestrial Manual method, and antigenicity verification by HI against reference antisera. The main process bottleneck on commercial scale is the batch-to-batch variance in haemagglutination titre from field isolates; this is managed by blending multiple inactivation lots after titre normalization to a fixed HA unit per dose, not by altering the final emulsion volume. Published data for autogenous EDSV antigen banks in specific poultry complexes are limited, but the operational principles are documented in regional veterinary biological product regulations.
For diagnostic haemagglutination inhibition (HI) panels and serological reagents, the inactivated EDSV antigen is supplied as a freeze-dried powder or as a concentrated aqueous suspension stabilized with sucrose-trehalose matrices. Lyophilization cycle parameters for EDSV antigen are not standardized across manufacturers; however, residual moisture in the final powder is controlled to ≤2.0% by coulometric Karl Fischer titration per Ph. Eur. 2.5.32, because higher moisture accelerates loss of haemagglutinating activity at 37 °C storage. The reconstituted antigen must show no visible aggregation and should retain a haemagglutination titre of at least 4 HA units/25 µL when mixed with chicken red blood cells. Freeze-dried EDSV antigen is used as a positive control in HI assays to monitor flock antibody levels after vaccination; it is not a vaccine route and is not administered to birds. In diagnostic batches, the powder is filled into borosilicate vials under nitrogen with headspace oxygen below 2.0% to reduce oxidative damage to surface glycoproteins. Dissolution time after adding 1.0 mL of sterile phosphate-buffered saline should be less than 60 s with gentle swirling, while turbidity measured at 650 nm remains below 0.05 absorbance units. Tablet and capsule formats are not used for HI panel controls because compression forces and excipient contact can denature the haemagglutinin; therefore, this API listing does not support solid oral diagnostic formats. The main technical limitation is that lyophilized antigen powder is hygroscopic and must be reconstituted in a laminar-flow hood at relative humidity below 40% to prevent clumping.
Concentrated aqueous EDSV antigen solutions are often supplied as a sterile intermediate for downstream blending into adjuvant premix systems, particularly when a regional vaccine manufacturer purchases the antigen rather than propagating the virus in-house. The concentrate is typically stabilized in 10 mM phosphate-buffered saline with 0.01% thiomersal or 0.2% formalin as a preservative, depending on the downstream compatibility profile. Dilution into the oil-based premix must occur under controlled vacuum and at 15–25 °C, with the aqueous phase added to the oil phase slowly at a rate not exceeding 5.0 L/min per 100 L batch in rotor-stator systems, because rapid addition creates transient water-rich zones that increase emulsion droplet size. The resulting emulsion is checked for electrical conductivity to confirm the external oil phase; a conductivity value below 10 µS/cm is generally associated with stable W/O inversion, while higher values suggest free aqueous pockets. For solution formats used in polyvalent premixes, pH drift after dilution must be controlled within 7.0–7.6, because EDSV haemagglutinin is sensitive to acid-induced conformational change below pH 6.0. The operational boundary for concentrates is that repeated freeze-thaw cycles are not recommended; published stability data support storage at 2–8 °C for up to 24 months for unpreserved concentrates only where the container closure system meets Ph. Eur. 3.2.1 requirements. Long-term stability of diluted aqueous premix solutions is limited, so downstream blending is typically scheduled within 72 h of dilution. No licensed EDSV vaccine uses tablet, capsule, or dry oral premix administration because the primary target tissue is the immune system via parenteral deposition; therefore, those solid dosage forms are not represented in actual manufacturing lines.
For batch release potency testing of inactivated EDSV vaccines, specified-pathogen-free (SPF) chickens are vaccinated at the minimum dose, followed by challenge with virulent EDSV or measurement of serological response. The inactivated antigen API used as a challenge control or reference standard must be aliquoted at a fixed haemagglutination titre to ensure that challenge doses produce consistent egg production loss and shell quality changes in control birds. Antigen concentration is verified by haemagglutination assay with chicken erythrocytes at 0.5% suspension, with the endpoint expressed as the reciprocal of the highest dilution producing complete haemagglutination. For challenge virus stocks, a titre of 10,000 embryo infectious doses per bird is frequently used in potency test protocols, but published EDSV-specific challenge models vary by strain and regulatory authority. The vaccine group is assessed for egg production maintenance and shell quality over a 21-day post-challenge observation period, with protection criteria requiring no significant drop in egg production relative to unvaccinated controls. The main operational limitation is that inactivated antigen cannot be used to prepare live challenge virus; it serves only as an antigenicity reference or serological positive control. Therefore, the API in its inactivated form is limited to manufacturing, quality control, and diagnostic applications, and does not generate a shed-and-spread risk in field use. Published data for the numerical correlation between in vitro HI titre and in vivo protection for EDSV are limited; vaccine producers therefore maintain in-house reference antigen banks calibrated against a standard challenge strain.
Competitive Egg Drop Syndrome Vaccine,Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Egg Drop Syndrome Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as an unpreserved whole-virus antigen concentrate derived from the EDSV-76 isolate of Duck atadenovirus A. Model identification is manufacturer-specific and linked to the master seed lot and reference serotype; no universal numeric model exists across pharmacopoeial monographs. The active fraction consists of clarified and concentrated allantoic fluid or cell culture supernatant containing inactivated virions with intact hexon, penton base, and fiber proteins. The API is not a finished vaccine. It is a biological active pharmaceutical ingredient intended for further aseptic formulation into injectable emulsions, reconstituted solutions, or stabilized lyophilized intermediates. Inactivation is performed before formulation with 0.10–0.20% formaldehyde at 37 °C for 16–24 h or with beta-propiolactone at 1:2000 dilution at 4 °C for 24 h. The resulting antigen is tested for absence of residual live virus by two blind passages in embryonated duck eggs and duck embryo cells. This API is primarily indicated for active immunization of laying hens and breeders against egg drop syndrome, with the objective of reducing production losses, depressed egg weight, and shell-quality defects caused by EDSV infection.
Inactivated EDSV is a heat-labile macromolecular assembly whose immunogenicity depends on the native conformation of the fiber, penton base, and hexon antigens. Tableting and capsule filling subject the antigen to compressive shear, frictional heating, and localized moisture redistribution. Lyophilized antigen cakes with residual moisture above 3.0% w/w by Ph. Eur. 2.5.12 and glass transition temperatures below 40 °C are vulnerable to collapse, microcrack formation, and loss of haemagglutination titre during die compaction. Direct compression of the intact antigen into tablets or hard capsules is therefore outside the validated formulation envelope unless the antigen is co-lyophilized with glass-forming stabilizers such as trehalose dihydrate or sucrose at excipient-to-antigen ratios of 1:1 to 4:1 and processed under relative humidity below 20% RH. Published data for oral solid-dose delivery of intact EDSV antigen in poultry is limited; these presentations are not recognized by the WOAH Terrestrial Manual as standard immunizing formats. Industrial use of this API remains confined to injectable emulsions and solution reconstitution.
Powders, granules, and premix carriers present additional destabilization mechanisms unrelated to mechanical stress. Dry-matrix adsorption of the antigen onto feed-grade calcium carbonate, wheat middlings, or dextrose monohydrate lowers water activity but exposes the virion surface to ionic and pH microenvironments during rehydration. If the lyophilized intermediate is intended for a solution or granulation step, the carrier must be pre-equilibrated at 2–8 °C and the contact time must not exceed 30 min before aqueous reconstitution. Solutions represent the most compatible non-injection format because reconstitution in chilled phosphate-buffered saline at pH 6.8–7.4 restores the native antigen conformation without introducing thermal or desiccation stress. The reconstituted solution should be held at 2–8 °C and used within 8 h. Tablets, capsules, powders, granules, and premix are therefore auxiliary descriptions for potential dry intermediate handling, not primary validated therapeutic presentations for EDSV vaccination.
Master seed lot propagation is conducted in specific-pathogen-free embryonated duck eggs or duck embryo fibroblast cultures. Allantoic fluid is harvested at 72–96 h post inoculation, clarified by continuous-flow centrifugation at 8,000 × g, and concentrated by 100 kDa tangential-flow filtration. Haemagglutination titre after concentration is generally adjusted to 2⁹–2¹² per 0.025 mL before inactivation; the exact release titre is manufacturer-specific and tied to the target potency of the finished vaccine. Inactivation validation follows a two-passage amplification protocol in embryonated duck eggs and susceptible duck embryo liver cell monolayers. Absence of haemagglutination and cytopathic effect in both passages is required. Residual formaldehyde is measured by Ph. Eur. 2.4.18 and controlled to ≤ 0.74 g/L in the aqueous concentrate. Beta-propiolactone residues are not detectable after hydrolysis at 37 °C for 2 h. Aseptic transfer and sterile filtration are not recommended for whole virion suspensions because filtration through 0.2 µm membranes can shear larger adenovirus aggregates and reduce antigen recovery; in-process bioburden control is therefore based on sterile filtration of buffer components and validated aseptic assembly.
Finished injectable vaccines are prepared by high-shear emulsification of the aqueous antigen with mineral oil or Montanide ISA 70 / 71 adjuvants. The oil-to-water ratio is commonly maintained at 70:30, with the aqueous phase held at 4±2 °C and the oil phase at 25±2 °C before homogenization. Emulsion viscosity at 25 °C, measured with a Brookfield rotational viscometer, ranges from 30 to 80 mPa·s depending on adjuvant grade and rotor-stator speed. Viscosity above 80 mPa·s is associated with droplet coalescence and reduced syringeability through 21-gauge needles. The finished monovalent vaccine is administered at 0.5 mL per bird by intramuscular or subcutaneous injection to pullets at 14–18 weeks of age, at least 2–4 weeks before onset of lay. Multivalent formulations with Newcastle disease, infectious bronchitis, infectious bursal disease, or avian reovirus antigens require pH adjustment to 6.8–7.4 and verification of antigen compatibility by potency testing after blending.
If the API is supplied as a lyophilized intermediate for solution reconstitution, the freeze-drying cycle must prevent cake collapse and preserve haemagglutination activity. Primary drying is performed at shelf temperatures from -25 °C to -15 °C at chamber pressures of 50–100 µbar. Secondary drying is conducted at 25 °C until residual moisture by Ph. Eur. 2.5.12 is ≤ 3.0% w/w. The lyoprotectant matrix typically contains trehalose dihydrate and arginine phosphate; cake appearance must be intact, without shrinkage, meltback, or visible cracking. Reconstitution in chilled phosphate-buffered saline or physiological saline should occur in 60 s or less with gentle swirling. The resulting solution remains usable for 8 h at 2–8 °C. These parameters are not transferable to finished oil emulsions; an aqueous antigen concentrate that has been frozen without lyoprotectant may show loss of haemagglutination titre and should not be used for commercial batch release.
Unlike a live EDSV construct, this inactivated whole-virus API does not replicate in the vaccinated bird, does not shed vaccine virus into eggs or litter, and cannot revert to virulence. Live EDSV vaccines are not widely deployed because of the potential for vertical transmission and because the virus is already egg-transmitted. Compared with subunit preparations expressing only fiber or hexon proteins, the whole-virus API retains the native antigenic array and generally induces broader haemagglutination-inhibition responses, but it is more sensitive to thermal and pH excursions during processing. Compared with finished mineral-oil vaccines, the API is an unpreserved active pharmaceutical ingredient; it requires continuous cold-chain maintenance at 2–8 °C, aseptic transfer, and immediate formulation after thawing. Once the bulk container is opened, the contents should be subdivided into sterile single-use containers or used within one working shift to reduce bacterial and fungal ingress under Grade C or equivalent controlled environments.
The aqueous antigen concentrate is released against the following control matrix. Where a monograph test is not applicable to the specific adjuvant or lyophilized format, the manufacturer’s validated method is substituted and must be documented in the marketing authorization file.
| Parameter | Reference method or standard | Acceptance criterion |
|---|---|---|
| Appearance of aqueous concentrate | Visual inspection | White to off-white homogeneous liquid; no visible flocculation |
| pH | Ph. Eur. 2.2.3 | 6.8–7.4 |
| Sterility | Ph. Eur. 2.6.1 | No growth after 14 days |
| Mycoplasma | Ph. Eur. 2.6.7 | Negative |
| Bacterial endotoxins | Ph. Eur. 2.6.14 | ≤ 1.0 EU/mL |
| Residual formaldehyde | Ph. Eur. 2.4.18 | ≤ 0.74 g/L |
| Residual moisture of lyophilized intermediate | Ph. Eur. 2.5.12 | ≤ 3.0% w/w |
| Pre-inactivation haemagglutination titre | Haemagglutination assay | 2⁹–2¹² per 0.025 mL |
| Inactivation confirmation | Two blind passages in embryonated duck eggs and duck embryo cells | No haemagglutination or cytopathic effect |
| Finished vaccine potency | WOAH Terrestrial Manual, Egg Drop Syndrome chapter | Mean HI titre ≥ 4 log2 at 21 days post vaccination in susceptible chickens |
Manufacturing-scale handling of the aqueous antigen concentrate has repeatedly shown that batch-to-batch variability in haemagglutination titre is higher when allantoic fluid is harvested later than 96 h or when clarification is delayed. Virus aggregates and host-cell debris increase viscosity and reduce subsequent membrane flux during tangential-flow filtration. Continuous-flow centrifugation with a disc-stack separator operating at 8,000 × g and a feed rate of 200–400 L/h is used to remove cell debris before concentration; lower centrifugal force leaves residual debris that fouls the 100 kDa cassettes and increases transmembrane pressure above 1.0 bar. Membrane batches that exceed 1.0 bar during ultrafiltration show reduced antigen recovery and higher protein contamination. These process limits are monitored by in-line pressure transducers and automatic shutoff; excursions require membrane integrity testing and a bioburden recheck before further processing.
Bulk aqueous antigen is stored at 2–8 °C for a shelf life assigned by the manufacturer, typically 6–12 months depending on buffer composition and container-closure integrity. Freezing of the aqueous concentrate without cryoprotectant is not recommended because ice-crystal formation disrupts the virion envelope and reduces haemagglutination titre by more than 1 log2 after a single freeze-thaw cycle. When freezing is unavoidable, the antigen is mixed with 10–20% w/v sucrose or trehalose dihydrate and frozen in single-use bags at -80 °C; thawing is performed in a 25 °C water bath under agitation for 15 min or less. Repeated freeze-thaw cycles are not permitted. The finished oil-emulsion vaccine should be stored at 2–8 °C and must not be frozen; emulsion breakdown, antigen phase separation, and loss of potency occur after freezing.
No direct mixing of the inactivated EDSV vaccine with live Newcastle disease or infectious bronchitis vaccines is recommended unless compatibility has been demonstrated by the marketing authorization holder. Inactivated mineral-oil emulsions can physically destabilize live vaccine diluents, reduce virus viability, and cause local tissue reactions if mixed in the same syringe. Separate injection sites and dedicated equipment are required. When simultaneous administration is prescribed, the inactivated EDSV vaccine is injected intramuscularly or subcutaneously, while the live respiratory vaccine is given by coarse spray, drinking water, or oculonasal route. Syringes used for oil-emulsion vaccines must be siliconized or equipped with low dead-space plungers to prevent dose variability above ±10% across 5,000-bird housing units.
The API differs from ready-to-use inactivated EDSV vaccines principally in the absence of adjuvant, preservative, and final isotonicity adjustment. Finished products are ready for injection and are usually formulated with thiomersal or gentamicin as preservative; the API is unpreserved to allow formulator-specific preservative selection. This absence of preservative reduces the risk of interference in multivalent antigen adsorption but increases cold-chain vulnerability. The API also permits custom antigen pooling before blending with Newcastle disease or infectious bronchitis components, whereas finished vaccines fix the antigen ratio at filling. Users performing bulk formulation must maintain sterile conditions and confirm final potency by serological testing in susceptible chickens; a finished product batch cannot be released on the basis of pre-inactivation titre alone.
In multivalent inactivated poultry vaccines, EDSV antigen can be displaced at the oil-water interface by higher-concentration Newcastle disease or avian influenza antigens. This displacement reduces the effective EDSV haemagglutination-inhibition titre and may create a serological gap despite adequate input antigen. Formulators therefore adjust the aqueous phase protein load to ≤ 25 mg/mL and the emulsifier concentration to 4–6% v/v of the oil phase. The EDSV antigen is added last under low-shear mixing at 200–300 rpm after the other antigens have been pre-emulsified. If the final emulsion is subjected to post-filling terminal sterilization, it must be validated because heat sterilization denatures the haemagglutinin; terminal filtration and terminal heat are not acceptable for this product class. Sterility is achieved by aseptic filtration of the aqueous phase and sterile assembly of the oil phase, followed by in-process bioburden monitoring after emulsification.
